Kuano

Kuano is applying advanced computational methods to solve the hardest problems in therapeutic design, accelerating the path to life-changing medicines. Look at our evidence here: At the core of our offering is the Quantum Lens technology, a proprietary platform combining cutting-edge quantum physics with other high-end in silico techniques. Our technology is redefining how the industry understands complex binding and reactivity, enabling the exploration of molecular interactions beyond simplified views, incorporating quantum chemistry, AI, and system dynamics to achieve unparalleled precision. Our rigorous quantum-informed simulations blended with sophisticated AI-assisted workflows, are deployed by an expert team of physicists and drug hunters, working collaboratively with our partners to decipher complex modes of binding and explore completely untapped areas of chemical space. Whether the problem is selectivity, potency, novelty or unlocking something ‘undruggable’, we help partners design novel inhibitors with confidence, precision, and deeper scientific insight. Kuano’s unique platform can address many target types and modalities, from classical enzyme inhibitors to allosteric binders, and including covalent ligand reactivity prediction, moving beyond traditional limitations to analyze reactivity across different amino acid residues considering the full biological context. This results in Quantum Fingerprints that capture subtle electronic and energetic features missed by conventional analysis. Founded on the belief that next-generation computation is key to solving disease, Kuano works closely with a broad range of organisations, including leading global pharmaceutical and biotech organisations. We are committed to developing new products and researching novel technologies to dramatically improve the efficiency and productivity of the drug discovery process for our clients.